Locher J T, Seybold K, Andres R Y, Schubiger P A, Mach J P, Buchegger F
Nucl Med Commun. 1986 Sep;7(9):659-70.
Successful detection of inflammatory lesions by planar scintigraphy and SPECT after injection of iodine-123 labelled monoclonal antibodies directed against human granulocytes (123I-Mabgc) is demonstrated. This new tracer has been compared with indium-111 labelled white blood cells (111In-WBC) in selected patients with proven infectious lesions. Scans were equally positive in all cases, but the methodical advantages of the new marker were obvious, namely, there is no need for cell separation and the images of inflammatory lesions were better defined. In addition, SPECT could be performed with 123I-Mabgc and allowed a better anatomic localization and a three-dimensional description of the lesions. No adverse reactions have been seen. It is concluded, therefore, that 123I-Mabgc is a promising agent for the detection of acute focal inflammatory lesions which may, with advantages, replace 111In-WBC.
已证实,注射针对人粒细胞的碘-123标记单克隆抗体(123I-Mabgc)后,通过平面闪烁扫描和单光子发射计算机断层扫描(SPECT)能成功检测炎症性病变。在选定的已证实有感染性病变的患者中,将这种新的示踪剂与铟-111标记的白细胞(111In-WBC)进行了比较。在所有病例中扫描结果均呈阳性,但新标记物的方法学优势明显,即无需细胞分离,且炎症性病变的图像更清晰。此外,使用123I-Mabgc可进行SPECT检查,能更好地对病变进行解剖定位和三维描述。未观察到不良反应。因此得出结论,123I-Mabgc是检测急性局灶性炎症性病变的一种有前景的试剂,可能具有优势,可取代111In-WBC。